World Investment Advisors Acquires 13,022 Shares of Zoetis Inc. $ZTS

World Investment Advisors lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 43.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,736 shares of the company’s stock after buying an additional 13,022 shares during the period. World Investment Advisors’ holdings in Zoetis were worth $5,052,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of ZTS. Nordea Investment Management AB increased its stake in Zoetis by 79.2% in the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after buying an additional 2,179,578 shares in the last quarter. Louisiana State Employees Retirement System purchased a new position in shares of Zoetis in the first quarter valued at about $2,542,000. Deutsche Bank AG boosted its stake in shares of Zoetis by 19.1% in the fourth quarter. Deutsche Bank AG now owns 5,558,183 shares of the company’s stock worth $699,331,000 after acquiring an additional 891,921 shares during the period. Seilern Investment Management Ltd boosted its stake in shares of Zoetis by 361.2% in the fourth quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company’s stock worth $41,957,000 after acquiring an additional 261,155 shares during the period. Finally, Assenagon Asset Management S.A. grew its position in shares of Zoetis by 134.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,631,619 shares of the company’s stock worth $205,290,000 after purchasing an additional 935,432 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

• Neutral Sentiment: Barclays reiterated its Hold rating on Zoetis, signaling the firm still sees limited near-term upside after the company’s recent earnings miss and softer-than-expected revenue growth. Barclays Sticks to Its Hold Rating for Zoetis (ZTS)
• Neutral Sentiment: Zoetis also drew attention for its dividend profile, with commentary focused on dividend quality as a potential support for income-oriented investors. Zoetis Inc (NYSE:ZTS) Dividend Quality Draws Focus
• Negative Sentiment: Multiple law firms issued reminders about an investor lawsuit deadline tied to alleged securities fraud, with claims centered on possible misstatements and omissions about product adoption. These notices can add overhang and keep sentiment weak around ZTS. ZTS IMPORTANT DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Zoetis Inc. Investors…
• Negative Sentiment: Additional class-action announcements from other firms reinforced the same legal overhang, keeping attention on the July 27 lead-plaintiff deadline rather than on business fundamentals. Zoetis Inc. (ZTS) Investors: July 27, 2026, Filing Deadline in Securities Fraud Class Action…

Zoetis Price Performance

NYSE:ZTS opened at $74.73 on Monday. The business’s 50-day moving average is $84.04 and its 200 day moving average is $109.31. Zoetis Inc. has a 12 month low of $71.47 and a 12 month high of $161.77. The company has a market capitalization of $31.33 billion, a P/E ratio of 12.39, a P/E/G ratio of 1.17 and a beta of 0.75. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). The firm had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities research analysts forecast that Zoetis Inc. will post 6.88 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 2.8%. The ex-dividend date is Monday, July 20th. Zoetis’s payout ratio is currently 35.16%.

Insider Activity at Zoetis

In other Zoetis news, Director Frank A. Damelio acquired 6,650 shares of the company’s stock in a transaction on Wednesday, May 13th. The stock was acquired at an average cost of $75.39 per share, with a total value of $501,343.50. Following the purchase, the director directly owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. This represents a 44.91% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Michael B. Mccallister bought 3,000 shares of Zoetis stock in a transaction dated Monday, May 11th. The stock was acquired at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the acquisition, the director owned 24,524 shares in the company, valued at approximately $1,906,986.24. The trade was a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 11,650 shares of company stock valued at $886,384 over the last 90 days. 0.22% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Citigroup decreased their target price on Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Stifel Nicolaus cut their price objective on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a report on Friday, June 26th. Argus reiterated a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. JPMorgan Chase & Co. lowered their target price on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Finally, TD Cowen cut their target price on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a research note on Tuesday, June 30th. Seven analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $126.92.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.